Lyell Competitors
| LYEL Stock | USD 25.26 0.58 2.24% |
Lyell Immunopharma vs Genelux Common Correlation
Excellent diversification
The correlation between Lyell Immunopharma and GNLX is -0.56 (i.e., Excellent diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Lyell Immunopharma and GNLX in the same portfolio, assuming nothing else is changed.
Moving together with Lyell Stock
Moving against Lyell Stock
| 0.79 | CUE | Cue Biopharma | PairCorr |
| 0.79 | MLEC | Moolec Science SA | PairCorr |
| 0.72 | AMRN | Amarin PLC | PairCorr |
| 0.7 | SPRB | Spruce Biosciences Common | PairCorr |
| 0.67 | MDCX | Medicus Pharma | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Lyell Immunopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Lyell Immunopharma Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Lyell Immunopharma and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Lyell and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Lyell Immunopharma does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Lyell Stock performing well and Lyell Immunopharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Lyell Immunopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ACIU | 4.03 | 0.28 | 0.08 | 0.17 | 4.79 | 9.84 | 27.64 | |||
| EDIT | 3.38 | (1.01) | 0.00 | (0.49) | 0.00 | 6.56 | 18.33 | |||
| ALLO | 3.53 | 0.39 | 0.12 | 0.26 | 3.24 | 9.76 | 21.23 | |||
| KYTX | 5.95 | 0.60 | 0.08 | 0.42 | 7.85 | 10.86 | 55.75 | |||
| SLN | 2.82 | (0.34) | 0.00 | (0.47) | 0.00 | 6.88 | 22.91 | |||
| LRMR | 3.57 | (0.17) | 0.00 | (0.44) | 0.00 | 6.96 | 21.85 | |||
| AMRN | 2.28 | (0.32) | 0.00 | (0.45) | 0.00 | 4.89 | 20.43 | |||
| CABA | 4.98 | 0.36 | 0.07 | 0.28 | 4.89 | 10.58 | 62.77 | |||
| ALDX | 3.57 | 0.06 | 0.00 | 0.37 | 4.47 | 6.27 | 42.93 | |||
| GNLX | 4.29 | (1.09) | 0.00 | (0.53) | 0.00 | 6.90 | 54.58 |
Cross Equities Net Income Analysis
Compare Lyell Immunopharma and related stocks such as AC Immune, Editas Medicine, and Allogene Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACIU | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | 10.7 M | 20.3 M | (7.1 M) | (26.4 M) | (51 M) | 45.4 M | (61.9 M) | (73 M) | (70.8 M) | (54.2 M) | (50.9 M) | (45.8 M) | (43.5 M) |
| EDIT | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (13.7 M) | (72.9 M) | (97.2 M) | (120.3 M) | (110 M) | (133.7 M) | (109.4 M) | (185.1 M) | (204.4 M) | (153.2 M) | (237.1 M) | (213.4 M) | (202.7 M) |
| ALLO | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (211.5 M) | (184.6 M) | (233.5 M) | (244.8 M) | (329.8 M) | (327.3 M) | (257.6 M) | (231.8 M) | (243.4 M) |
| KYTX | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (28.9 M) | (60.4 M) | (127.5 M) | (114.7 M) | (109 M) |
| SLN | (874 K) | (5.7 M) | (26.3 M) | (9 M) | (11.1 M) | (6.6 M) | (8.4 M) | (1.6 M) | (18.4 M) | (19.6 M) | (32.5 M) | (39.4 M) | (50.3 M) | (43.3 M) | (45.3 M) | (40.8 M) | (38.7 M) |
| LRMR | (13.2 M) | (13.2 M) | (13.9 M) | (14 M) | (36.6 M) | (74.3 M) | (57.9 M) | (52 M) | (61.4 M) | (23.1 M) | (42.3 M) | (50.3 M) | (34.2 M) | (36.9 M) | (80.6 M) | (72.5 M) | (68.9 M) |
| AMRN | 900 K | (69.4 M) | (179.2 M) | (166.2 M) | (56.4 M) | (115.2 M) | (86.3 M) | (67.9 M) | (116.4 M) | (22.6 M) | (18 M) | 7.7 M | (105.8 M) | (59.1 M) | (82.2 M) | (74 M) | (77.7 M) |
| CABA | (250 K) | (250 K) | (250 K) | (250 K) | (250 K) | (250 K) | (250 K) | (250 K) | (12.2 M) | (15.1 M) | (32.5 M) | (45.5 M) | (51.8 M) | (67.7 M) | (115.9 M) | (104.3 M) | (99.1 M) |
| ALDX | (2.4 M) | (2.4 M) | (23.1 M) | 13.1 M | (5.2 M) | (12.1 M) | (18.7 M) | (22.3 M) | (38.9 M) | (60.8 M) | (37.6 M) | (57.8 M) | (62 M) | (37.5 M) | (55.9 M) | (50.3 M) | (47.8 M) |
| GNLX | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (14.9 M) | (17.8 M) | (5.2 M) | (28.3 M) | (29.9 M) | (26.9 M) | (28.2 M) |
Lyell Immunopharma and related stocks such as AC Immune, Editas Medicine, and Allogene Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Lyell Immunopharma financial statement analysis. It represents the amount of money remaining after all of Lyell Immunopharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Lyell Immunopharma Competitive Analysis
The better you understand Lyell Immunopharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Lyell Immunopharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Lyell Immunopharma's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Lyell Immunopharma Competition Performance Charts
Five steps to successful analysis of Lyell Immunopharma Competition
Lyell Immunopharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Lyell Immunopharma in relation to its competition. Lyell Immunopharma's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Lyell Immunopharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Lyell Immunopharma's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Lyell Immunopharma, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Lyell Immunopharma position
In addition to having Lyell Immunopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Volatility ETFs Thematic Idea Now
Volatility ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Volatility ETFs theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Volatility ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Lyell Immunopharma Correlation with its peers. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (22.75) | Revenue Per Share | Quarterly Revenue Growth (0.56) | Return On Assets | Return On Equity |
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.